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ABSTRACT  
Background and aims: Next generation sequencing approaches have tremendously improved 
the diagnosis of rare genetic diseases. It may however be faced with difficult clinical 
interpretation of variants. Inherited enzymatic diseases provide an invaluable possibility to 
evaluate the function of the defective enzyme in human cell biology. This is the case for 
respiratory complex III, which has 11 structural subunits and requires several assembly 
factors. An important role of complex III in liver function is suggested by its frequent 
impairment in human cases of genetic complex III defects.  
Methods: We report the case of a child with complex III defect and acute liver dysfunction 
with lactic acidosis, hypoglycemia, and hyperammonemia. Mitochondrial activities were 
assessed in liver and fibroblasts using spectrophotometric assays. Genetic analysis was done 
by exome followed by Sanger sequencing. Functional complementation of defective 
fibroblasts was performed using lentiviral transduction followed by enzymatic analyses and 
expression assays.  
Results: Homozygous, truncating, mutations in LYRM7 and MTO1, two genes encoding 
essential mitochondrial proteins were found. Functional complementation of the complex III 
defect in fibroblasts demonstrated the causal role of LYRM7 mutations. Comparison of the 
patient’s clinical history to previously reported patients with complex III defect due to nuclear 
DNA mutations, some actually followed by us, showed striking similarities allowing us to 
propose common pathophysiology.  
Conclusions: Profound complex III defect in liver does not induce actual liver failure but 
impedes liver adaptation to prolonged fasting leading to severe lactic acidosis, hypoglycemia, 
and hyperammonemia, potentially leading to irreversible brain damage. 
 
Lay summary 
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The diagnosis of rare genetic disease has been tremendously accelerated by the development 
of high throughput sequencing technology. In this paper we report the investigations that have 
led to identify LYRM7 mutations causing severe hepatic defect of respiratory complex III. 
Based on the comparison of the patient’s phenotype with other cases of complex III defect, 
we propose that profound complex III defect in liver does not induce actual liver failure but 
impedes liver adaptation to prolonged fasting. 
6 
 
Introduction 
Classical mitochondrial diseases result from defects of the mitochondrial oxidative 
phosphorylation pathway (OXPHOS). They present with diverse clinical features [1]. Liver 
failure however is frequently reported in severe pediatric cases [2]. Its mitochondrial origin is 
often diagnosed by the presence of defective OXPHOS activities in liver. However, because 
of the possibility of improper sample preservation or nature, the diagnosis cannot solely rely 
on these defects but requires identification of the genetic cause of the disease. That 
identification has recently been tremendously facilitated by next generation sequencing.  
Genetic causes of mitochondrial liver failure may be classified with respect to the type of 
OXPHOS defect. The most frequent are combined defects involving OXPHOS complexes 
with mitochondrial DNA (mtDNA)-encoded subunits, caused often by mtDNA depletion 
(profound decrease of the mtDNA amount) [3-6] or defects of the mtDNA translation [7-9]. In 
this group liver functions are globally altered associating synthesis failure with coagulopathy, 
cytolysis, and cholestasis often progressing towards cirrhosis. These diseases are often 
multisystem disorders, associating neurological deficits to the liver failure. 
Much rarer cases of liver failure have been associated with an isolated OXPHOS defect, 
which is most often respiratory complex III (ubiquinol cytochrome c oxidoreductase, EC 
1.10.2.2). In these cases the liver alterations seemed to differ according to the causal gene. 
Global liver failure, resembling that observed with multiple OXPHOS defects, has been 
described in severe, early onset, diseases due to mutations of BCS1L gene encoding a 
complex III assembly factor [10, 11], acute episodes of hypoglycemia and hyperammonemia 
have been associated with mutations of UQCRB, CYC1 and UQCRC2 genes encoding 
complex III structural subunits [12-14], and normal liver functions have been reported in 
diseases due to mutations of genes encoding either complex III assembly factors (TTC19 [15], 
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UQCC2 [16], UQCC3 [17] and LYRM7 [18, 19]) or structural subunits (MT-CYB [20], 
UQCRQ [21]). The role of complex III in liver function thus appears disputable.  
We here report a patient with liver complex III defect. Although exome sequencing revealed 
two genes, MTO1 and LYRM7, both carrying homozygous truncating mutations and both 
encoding essential mitochondrial proteins, functional complementation by lentiviral vectors 
demonstrated that the LYRM7 mutations were causing the complex III defect. Comparison of 
the patient’s clinical history to previously reported patients with complex III defect, some 
actually followed by us, led us to propose common pathophysiology for several complex III 
defects whereby profound complex III defect in liver does not induce actual liver failure but 
impedes liver adaptation to prolonged fasting. Lack of appropriate metabolic treatment of the 
fasting-induced lactic acidosis, hypoglycemia, and hyperammonemia may result in 
irreversible brain damage. 
Material, patient and methods 
Patient 
The patient was the third child of first cousins parents. She first presented at 6 months of age 
with ketoacidosis, hyperglycemia and glycosuria. Intravenous injection of insulin induced 
hypoglycemia without correcting ketonuria. The child was transferred to La Rabta hospital in 
Tunis. At her arrival she was hypotonic, polypneic and presented with mild hepatomegaly. 
Biological tests revealed compensated metabolic acidosis (pH 7.42, bicarbonate 15.7 mM, 
pCO2 24 mmHg), hyperlactatemia (5.2 mM), and hyperlactatorrachia (8 mM) with mild 
hyperammonemia (64 µM, N<50), but normal liver enzymes and coagulation factors. Very 
high lactate, 3 OH butyrate and 2-ketoglutarate were found on urinary organic acids profiling. 
Electrocardiogram, echocardiography, kidney functions, and electroencephalogram were 
normal. 
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The further disease course was marked by episodes of metabolic crises associating metabolic 
acidosis with hyperlactatemia, ketonuria and hypoglycemia; ammonia was not measured. A 
severe episode, lasting three days and associated with coma, occurred at one year of age. It 
was followed by irreversible neurological damage with loss of contact, profound axial 
hypotonia, peripheral hypertonia, horizontal nystagmus, and deglutition troubles. Hepatic and 
skin biopsies were performed at that period. The child died shortly afterwards during a 
recurrent metabolic crisis at 20 months of age. 
Samples 
All analyses were performed after written informed consent from the parents of the child 
according to the local institution rules. A needle liver biopsy was immediately frozen in liquid 
nitrogen, stored at -80°C until enzymatic assays. Primary fibroblasts were derived from a 
forearm skin biopsy as described in [22].  
DNA samples were obtained from liver and fibroblasts using standard procedure with SDS 
and proteinase K digestion followed by phenol extraction and isopropanol precipitation. DNA 
samples from blood were obtained using QiaAmp DNA minikit (Qiagen, Courtaboeuf, 
France). RNA samples from fibroblasts were obtained using the miRNeasy kit (Qiagen, 
Courtaboeuf, France). 
Mitochondrial fractions were prepared from 2 T175 fibroblasts flasks according to [23]. 
Mitochondrial activities 
Spectrophotometric assays for the respiratory complexes I, II, III and IV, as well as citrate 
synthase activities were performed according to [24].  
Western blot analysis 
Proteins from mitochondrial pellets were separated by blue native polyacrylamide gel 
electrophoresis [25] or by SDS-PAGE on a linear 4 to 20% gradient polyacrylamide gel 
(Biorad, Hertfordshire, UK). Antibodies against UQCRC2 and UQCRFS1 were kindly given 
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by Dr Catherine Godinot, France [26], antibodies against MT-ND1 and against MT-CO2 were 
produced in our group [27]; the other antibodies were commercially available: anti-SDHA, 
anti-ATP5B and anti-LYRM7 were from Abcam (France), anti-MTO1 from Proteintech 
(USA) and anti-ACTB from Sigma-Aldrich (USA). They were visualized using peroxidase-
conjugated secondary antibodies (Sigma-Aldrich, USA) and Pierce™ ECL Western Blotting 
Substrate (Life Technologies, USA). Western blot signals were recorded on a Fusion ultra-
sensitive camera platform (Vilber Lourmat, Germany) and quantified using the Fusion 
attached software. Results were normalized to the control run on the same gel and to complex 
II, either the whole complex II after blue native gel electrophoresis or SDHA subunit after 
SDS gel electrophoresis.  
Exome sequencing 
Exome sequencing and variant filtering was essentially performed as described previously 
[28]. In brief, coding DNA fragments were enriched with the SureSelect Human All Exon 
50Mb V4 Kit (Agilent, Santa Clara, CA, USA) and sequencing was performed on a 
HiSeq2000 system (Illumina, San Diego, CA, USA). Reads were aligned to the human 
genome assembly hg19 (UCSC Genome Browser) with Burrows-Wheeler Aligner (BWA, 
version 0.7. 5) and detection of genetic variation was performed using SAMtools (version 
0.1.19), PINDEL (version 0.2.5a7), and ExomeDepth (version 1.0.0). 96.9 % of the target was 
covered at least 20-fold. 
Lentiviral gene transfer 
LYRM7 cDNA was purchased from DNASU Plasmid Repository (Clone ID HsCD00514704) 
and cloned into the pLenti6.3/V5-TOPO vector system (Invitrogen, Life technologies) for 
subsequent lentiviral-mediated expression in skin fibroblast cell lines using the ViraPower 
HiPerform Lentiviral TOPO Expression Kit (Invitrogen, Life technologies) [29]. The 
corresponding MTO1 clone was already available [30]. We also constructed a third lentivirus 
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for expression of the MTO1 cDNA sequence but with Geneticin resistance [31]. Stably 
transduced fibroblasts were selected using Blasticidin (Invitrogen) and/or Geneticin (Sigma-
Aldrich). 
RNA analyses 
Reverse transcription of 2 micrograms total RNA was performed with the Transcriptor First 
strand cDNA synthesis kit (Roche Diagnostics, USA). The cDNA steady-state was quantified 
using LightCycler 480 SybrGreen master mix (Roche Diagnostics, USA). Serial dilutions of 
linearized pGEM-T plasmids with the amplification products as insert, allowed absolute 
quantification of the cDNA in copy numbers per µL. Results were expressed as copy numbers 
per 1000 ACTB copies. 
Statistical methods 
Statistics were performed with SigmaPlot 12.5 software. Non parametric tests were used 
unless the data were shown to have a normal distribution allowing the use of parametric tests. 
The numbers given indicate independent measurements. Mean comparisons were performed 
with Mann and Whitney test or unpaired Student t test. The Holm-Sidak test for multiple 
comparisons was used to address the relative influence of lentivirus infection, genotype and 
their interaction. 
 
Results 
Complex III defect was present in the patient’s liver and fibroblasts 
Spectrophotometric assays of the respiratory chain activities in the patient’s liver biopsy 
disclosed a profound defect in complex III (Table 1). Other mitochondrial activities were 
either normal or elevated, in particular rotenone sensitive complex I activity, which is highly 
sensitive to improper preservation. Significant decrease of complex III activity was also 
observed in cultured skin fibroblasts from the patient but with complex III residual activity 
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higher than in liver, without significant impact on the combined complex II+III activity. 
Complex IV activity appeared mildly decreased in fibroblasts, the defect only being 
significant when complex IV activity was normalized to citrate synthase activity (p=0.031). 
Analysis of the OXPHOS composition of fibroblasts by blue native polyacrylamide gel 
electrophoresis showed that the amount of complex III was decreased while that of complexes 
I, II, IV and V was close to controls (Figure 1A). SDS-PAGE of complex III subunits showed 
an almost normal amount of UQCRC2 that contrasted with a severe decrease of UQCRFS1 
(Figure 1B). Unassembled subunits are efficiently degraded by the mitochondrial quality 
control [32]. UQCRC2 is one of the first subunits assembled to the complex whereas 
UQCRFS1 is the last subunit added [33]. The observed pattern could therefore suggest either 
an alteration of UQCRFS1 itself or a complex III assembly defect. 
Search for the genetic alteration causing complex III defect disclosed two candidate genes 
Direct sequencing of the coding sequences of UQCRFS1 and other genes implicated in human 
complex III defects (BCS1L, MT-CYB, UQCRB, UQCRQ and CYC1) disclosed only normal 
sequence or known polymorphisms. We thus turned to whole exome sequencing. Given that 
the observed pattern was in line with autosomal recessive inheritance and the clinical 
phenotype was very rare, we focused on genes carrying homozygous or possible compound 
heterozygous rare variants (Minor Allele Frequency <0.1 % in 5,000 in house controls and the 
Washington Exome Variant Server). This search identified 22 genes. Two of these genes, 
LYRM7 and MTO1, encode mitochondrial proteins [34] and variants in both have been linked 
to OXPHOS defects. Moreover, in both genes, mutations were homozygous predicted 
truncating variants. In LYRM7 (NM_181705.3) it was a c.[52delA];[52delA], 
p.[Arg18Aspfs*12];[Arg18Aspfs*12] frameshift variant and in MTO1 (NM_012123.3) it was 
a c.[1996C>T];[1996C>T], p.[Arg666*];[Arg666*] stop variant (Figure 2). The modification 
induced by the mutation and the phylogenetic conservation of the proteins are shown in Table 
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2. LYRM7 encodes for a small mitochondrial protein (104 aminoacids, molecular weight 11.9 
kDa) belonging to the LYR family. It has recently been identified as a complex III late 
assembly factor [35] and found mutated in a severe infantile case of complex III defect with 
early onset severe encephalopathy and lactic acidosis [18]. MTO1 encodes for a mitochondrial 
protein (732 aminoacids, molecular weight after mitochondrial processing 74 kDa [36]), 
which has been shown to play a role in mitochondrial tRNA post transcriptional modifications 
[37]. It has first been thought to be involved in human pathology as a potential modifying 
factor for mtDNA rRNA mutations [38] but was later associated with cases of hypertrophic 
cardiomyopathy with combined OXPHOS defect and lactic acidosis [36].  
We verified the presence of the LYRM7 and MTO1 mutations by Sanger sequencing and 
analyzed their segregation within the family (Figure 2). For both genes, the mutation was 
found in a homozygous state in the patient, heterozygous in both her parents as well as in one 
of her healthy siblings, and absent in her second healthy sibling. Familial analysis thus could 
not help to exclude one of the two genes. 
Complementation assays demonstrated that LYRM7 mutations were causing the complex 
III defect. 
To assess the causal role of the mutation we constructed lentiviral vectors carrying the wild 
type cDNA sequence of LYRM7 (LYRM7-lentivirus) or MTO1 (MTO1-lentivirus) associated 
with blasticidin resistance. In order to test the combined effect of the two mutations, we also 
constructed a third lentivirus carrying the wild type MTO1 cDNA sequence but with 
neomycin resistance in order to be independently selected from the virus carrying LYRM7 
cDNA. Control transfection were performed with lentiviruses only carrying blasticidin or 
neomycin resistance. 
Transduction was performed in fibroblasts from the patient and a control. Its efficacy was 
shown in all transduced cells by the significant expression of the messenger RNA coding 
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either for resistance to blasticidin or neomycin or for LYRM7 or MTO1 (Figure 3A). Of note 
both LYRM7 and MTO1 messenger RNA were not significantly decreased in the non-
transduced patient’s cells as compared to non-transduced control cells suggesting absence of 
nonsense-mediated decay of the mutant messenger RNA. 
Mitochondrial activities were assayed after more than ten generations under antibiotic 
selection (Figure 3B). Significant interaction between genotype and lentiviral infection was 
only shown for complex III activity (two way ANOVA p=0.006). Infection with the LYRM7-
lentivirus, whether alone or in combination with the MTO1-lentivirus, significantly increased 
complex III activity in patient’s but not in control cells. Complex II or citrate synthase 
activities did not show any significant variation among genotypes or after lentiviral infection, 
whatever viruses used. The combined transduction with both MTO1- and LYRM7-lentivirus 
had significant impact on complex IV activity in both patient and control cell lines. The 
initially mild complex IV defect of the patient’s cells was further decreased while control 
cells presented with significant decrease of their complex IV activity. The toxicity of the 
repeated lentivirus infection or of long-term antibiotics treatment was ruled out by the normal 
mitochondrial activities of cells transduced with empty lentiviruses encoding either blasticidin 
or neomycin resistance, alone or in combination (Supplemental Figure 1). The relatively high 
passage number reached by the cells when combined transduction was applied could underlie 
the observation. In any case these difficulties prevented to elucidate the potential relative 
influence on the biochemical phenotype of MTO1 and LYRM7 mutations. 
Functional complementation was further confirmed by western blot analysis showing 
restoration of UQCRFS1 protein steady-state by LYRM7-lentivirus infection, either alone or 
in combination with MTO1-lentivirus, but not by MTO1-lentivirus alone (Figure 4).  
 
Discussion 
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This study exemplifies some of the difficulties encountered with next generation sequencing. 
The unbiased and efficient whole exome-next generation sequencing is bound to find 
numerous homozygous genetic variants in consanguineous families, such as the one herein 
reported. Filtering is mandatory to reduce the number of candidate genes. Based on bi-allelic 
variants plus the nature of the mutation and a known mitochondrial function of the encoded 
protein in our case, it reduced the number of candidate genes to only two, both already 
associated with OXPHOS defects. Both mutations are predicted to result in protein truncation. 
However, the LYRM7 mutation leaves only 17 amino acids unchanged, while the MTO1 
mutation leaves a 665 amino acids shortened by 27 amino acids. Western blot analysis 
showed that LYRM7 protein could not be detected in the patient’s samples in contrast to 
control. This was not the case for MTO1 protein. The patient’s phenotype resembled that of 
other complex III deficiencies while her normal heart function contrasted with the 
cardiomyopathy usually reported in patients with MTO1 mutations. The patient’s complex III 
defect was directly explained by the role of LYRM7 in complex III assembly while her normal 
complex I activity contrasted with the complex I defect, isolated or combined with complex 
IV, which is associated with MTO1 mutations. Finally functional complementation was 
decisive in linking the complex III defect with LYRM7 mutations while showing no impact of 
transduction with MTO1-lentivirus. Despite the clear causative link between LYRM7 mutation 
and complex III deficiency, a potential harmful effect of the MTO1 variant on the patient 
clinical phenotype could not be excluded.  
The severe metabolic crises without actual liver failure observed with LYRM7 defect 
exemplify OXPHOS contribution to liver role during prolonged fasting when both β oxidation 
and gluconeogenesis are concomitantly activated in liver (Figure 5). Their electrons then 
converge towards complex III either via complex II (oxidizing succinate into fumarate) or 
complex I (oxidizing the NADH coming from the Krebs cycle or β oxidation). A defective 
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complex III, unable to sustain the increased electron flux, will provoke the slowing down of 
the Krebs cycle at its four oxido-reduction steps, succinate dehydrogenase and the three 
NAD-dependent dehydrogenases. Because all their intermediary metabolites pass through the 
Krebs cycle, gluconeogenic substrates are produced to a lesser extent explaining the 
occurrence of hypoglycemia. Hyperammonemia on the other hand is explained by the 
decrease of oxaloacetate, which reduces the export of aspartate leading to defect of the urea 
cycle cytosolic step where aspartate is condensed with citrulline to give argininosuccinate. 
Hypoglycemia and hyperammonemia observed during the metabolic crises of the patients thus 
reflect altered metabolism and not actual liver insufficiency. Consequently they are 
completely reversible provided intensive nutritional care restores the metabolism towards a 
fed state, with concomitant inhibition of β oxidation and gluconeogenesis. These metabolic 
crises are expected to be less frequent and less severe with increasing age because the period 
of time when glycogen breakdown suffices for the maintenance of blood glucose 
progressively increases [39]. That spontaneous improvement with age has been observed with 
the patients with UQCRB or CYC1 mutations [12, 13]. 
Comparison of the clinical presentation of the patient herein reported disclosed a pattern 
common to several other cases of complex III defect, including the first two patients with 
LYRM7 mutations [18], and the patients with UQCRB [12], CYC1 [13] or UQCRC2 [14] 
mutations (Table 3). All these genes but LYRM7 encode complex III structural subunits 
without tissue-specific isoform. The sole clinical difference among these diverse complex III 
defects was the occurrence of encephalopathy in the patients with LYRM7 mutations [18, 19]. 
The possibility to maintain brain functions despite the presence of a profound complex III 
defect is demonstrated by the patients with mutations in UQCRB [12] or CYC1 [13], two of 
whom, followed by one of us, have now reached adulthood with normal brain functions.  
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The mechanism underlying the encephalopathy of patients with LYRM7 mutations is essential. 
Indeed it could not be avoided if it were due to the role of LYRM7 in brain whereas it would 
be at least partially prevented by appropriate intensive metabolic treatment if it were a 
consequence of the severe metabolic disturbances due the liver defect. The latter mechanism 
is suggested by the initially normal neurological status of the patients and by the occurrence 
of encephalopathy as subacute episodes of deterioration, often triggered by febrile illness [18, 
19]. The severe metabolic episodes (with blood pH dropping to 6.78 or prolonged coma) 
observed in our patient and in the first one reported [18] would also fit with a toxic 
encephalopathy. The patients most recently reported presented however with a different 
clinical pattern despite similar or identical LYRM7 mutations [19]. They did not present with 
severe metabolic disturbances, in accordance with their later onset and prolonged survival, but 
had significant encephalopathy with distinct leukoencephalopathy. However, because of the 
potential therapy, it would be important to evaluate these patients metabolic status during one 
of their episodes of subacute encephalopathy before definitely excluding a toxic component to 
their brain damage. 
If the encephalopathy is essentially due to the role of LYRM7 in brain, the 
genotype/phenotype relationship of LYRM7 mutations would resemble that of BCS1L and 
TTC19, encoding other complex III assembly factors, where encephalopathy is either constant 
(TTC19) or very frequent (BCS1L) [40, 41]. In both cases, encephalopathy occurs in the 
absence of acute metabolic crises. Most importantly, TTC19 mutations spare liver function 
whereas severe BCS1L mutations induce generalized liver dysfunction, progressing towards 
cirrhosis. Part of these differences might be explained by the fact that, in contrast to structural 
subunits, assembly factors are expected to have other functions in addition to their role 
OXPHOS assembly. Indeed both BCS1L and TTC19 proteins have been involved in other 
protein-protein interactions [15, 42]. Mutations of UQCC2 [16] and UQCC3 [17], both 
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encoding complex III assembly factor and associated with human disease, have each been 
reported only once in very young patients preventing to reliably ascertain their phenotype.  
In conclusion: profound complex III defect in liver induces severe lactic acidosis, ketosis, 
hypoglycemia, and hyperammonemia that occur after prolonged fasting and may induce 
irreversible brain damage in the absence of intensive metabolic care.  
 
Acknowledgments 
This work was supported by grants from the FRM (Fondation pour la Recherche Médicale) 
grant DPM20121125550 to AL; from the Association Française contre les Myopathies (AFM)  
to AL and Association contre les Maladies Mitochondriales (AMMi) to AL; German 
Bundesministerium für Bildung und Forschung (BMBF) through funding of the E-Rare 
project GENOMIT (01GM1207) (TM, HP); German Network for mitochondrial disorders 
(mitoNET, 01GM1113C) (TM, HP).  
 
References 
[1] DiMauro S. Mitochondrial diseases. Biochim Biophys Acta 2004;1658:80-88. 
[2] Auré K, C Jardel, A Lombès. Mitochondrial diseases: molecular mechanisms, clinical 
presentations and diagnosis investigations. Ann Pathol 2005;25:270-281. 
[3] Labarthe F, D Dobbelaere, L Devisme, A De Muret, C Jardel, JW Taanman, et al. 
Clinical, biochemical and morphological features of hepatocerebral syndrome with 
mitochondrial DNA depletion due to deoxyguanosine kinase deficiency. J Hepatol 
2005;43:333-341. 
[4] Spinazzola A, C Viscomi, E Fernandez-Vizarra, F Carrara, P D'Adamo, S Calvo, et al. 
MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic 
mitochondrial DNA depletion. Nat Genet 2006;38:570-575. 
18 
 
[5] Sarzi E, S Goffart, V Serre, D Chretien, A Slama, A Munnich, et al. Twinkle helicase 
(PEO1) gene mutation causes mitochondrial DNA depletion. Ann Neurol 2007;62:579-587. 
[6] Naviaux RK, KV Nguyen. POLG mutations associated with Alpers' syndrome and 
mitochondrial DNA depletion. Ann Neurol 2004;55:706-712. 
[7] Coenen MJ, H Antonicka, C Ugalde, F Sasarman, R Rossi, JG Heister, et al. Mutant 
mitochondrial elongation factor G1 and combined oxidative phosphorylation deficiency. N 
Engl J Med 2004;351:2080-2086. 
[8] Zeharia A, A Shaag, O Pappo, AM Mager-Heckel, A Saada, M Beinat, et al. Acute 
infantile liver failure due to mutations in the TRMU gene. Am J Hum Genet 2009;85:401-
407. 
[9] Vedrenne V, L Galmiche, D Chretien, P de Lonlay, A Munnich, A Rotig. Mutation in 
the mitochondrial translation elongation factor EFTs results in severe infantile liver failure. J 
Hepatol 2012;56:294-297. 
[10] de Lonlay P, I Valnot, A Barrientos, M Gorbatyuk, A Tzagoloff, JW Taanman, et al. 
A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency in 
patients with tubulopathy, encephalopathy and liver failure. Nat Genet 2001;29:57-60. 
[11] Visapaa I, V Fellman, J Vesa, A Dasvarma, JL Hutton, V Kumar, et al. GRACILE 
syndrome, a lethal metabolic disorder with iron overload, is caused by a point mutation in 
BCS1L. Am J Hum Genet 2002;71:863-876. 
[12] Haut S, M Brivet, G Touati, P Rustin, S Lebon, A Garcia-Cazorla, et al. A deletion in 
the human QP-C gene causes a complex III deficiency resulting in hypoglycaemia and lactic 
acidosis. Hum Genet 2003;113:118-122. 
[13] Gaignard P, M Menezes, M Schiff, A Bayot, M Rak, H Ogier de Baulny, et al. 
Mutations in CYC1, encoding cytochrome c1 subunit of respiratory chain complex III, cause 
insulin-responsive hyperglycemia. Am J Hum Genet 2013;93:384-389. 
19 
 
[14] Miyake N, S Yano, C Sakai, H Hatakeyama, Y Matsushima, M Shiina, et al. 
Mitochondrial complex III deficiency caused by a homozygous UQCRC2 mutation presenting 
with neonatal-onset recurrent metabolic decompensation. Hum Mutat 2013;34:446-452. 
[15] Ghezzi D, P Arzuffi, M Zordan, C Da Re, C Lamperti, C Benna, et al. Mutations in 
TTC19 cause mitochondrial complex III deficiency and neurological impairment in humans 
and flies. Nat Genet 2011;43:259-263. 
[16] Tucker EJ, BF Wanschers, R Szklarczyk, HS Mountford, XW Wijeyeratne, MA 
van den Brand, et al. Mutations in the UQCC1-interacting protein, UQCC2, cause human 
complex III deficiency associated with perturbed cytochrome b protein expression. PLoS 
Genet 2013;9:e1004034. 
[17] Wanschers BF, R Szklarczyk, MA van den Brand, A Jonckheere, J Suijskens, R 
Smeets, et al. A mutation in the human CBP4 ortholog UQCC3 impairs complex III 
assembly, activity and cytochrome b stability. Hum Mol Genet 2014;23:6356-6365. 
[18] Invernizzi F, M Tigano, C Dallabona, C Donnini, I Ferrero, M Cremonte, et al. A 
homozygous mutation in LYRM7/MZM1L associated with early onset encephalopathy, lactic 
acidosis, and severe reduction of mitochondrial complex III activity. Hum Mutat 
2013;34:1619-1622. 
[19] Dallabona C, TE Abbink, R Carrozzo, A Torraco, A Legati, CG van Berkel, et al. 
LYRM7 mutations cause a multifocal cavitating leukoencephalopathy with distinct MRI 
appearance. Brain 2016;139:782-794. 
[20] Meunier B, N Fisher, S Ransac, JP Mazat, G Brasseur. Respiratory complex III 
dysfunction in humans and the use of yeast as a model organism to study mitochondrial 
myopathy and associated diseases. Biochim Biophys Acta 2013;1827:1346-1361. 
20 
 
[21] Barel O, Z Shorer, H Flusser, R Ofir, G Narkis, G Finer, et al. Mitochondrial complex 
III deficiency associated with a homozygous mutation in UQCRQ. Am J Hum Genet 
2008;82:1211-1216. 
[22] Auré K, K Mamchaoui, P Frachon, GS Butler-Browne, A Lombès, V Mouly. Impact 
on oxidative phosphorylation of immortalization with the telomerase gene. Neuromuscul 
Disord 2007;17:368-375. 
[23] Klement P, LG Nijtmans, C Van den Bogert, J Houstek. Analysis of oxidative 
phosphorylation complexes in cultured human fibroblasts and amniocytes by blue-native-
electrophoresis using mitoplasts isolated with the help of digitonin. Anal Biochem 
1995;231:218-224. 
[24] Medja F, S Allouche, P Frachon, C Jardel, M Malgat, BM de Camaret, et al. 
Development and implementation of standardized respiratory chain spectrophotometric assays 
for clinical diagnosis. Mitochondrion 2009;9:331-339. 
[25] Schagger H, G von Jagow. Blue native electrophoresis for isolation of membrane 
protein complexes in enzymatically active form. Anal Biochem 1991;199:223-231. 
[26] Legros F, E Chatzoglou, P Frachon, H Ogier de Baulny, P Laforêt, C Jardel, et al. 
Molecular consequences of novel mutations in the human cytochrome b gene. Eur J Hum 
Genet 2001;9:510-518. 
[27] Barthélémy C, H Ogier de Baulny, J Diaz, MA Cheval, P Frachon, N Romero, et al. 
Late-onset mitochondrial DNA depletion: DNA copy number, multiple deletions, and 
compensation. Ann Neurol 2001;49:607-617. 
[28] Haack TB, B Haberberger, EM Frisch, T Wieland, A Iuso, M Gorza, et al. Molecular 
diagnosis in mitochondrial complex I deficiency using exome sequencing. J Med Genet 
2012;49:277-283. 
21 
 
[29] Kornblum C, TJ Nicholls, TB Haack, S Scholer, V Peeva, K Danhauser, et al. Loss-
of-function mutations in MGME1 impair mtDNA replication and cause multisystemic 
mitochondrial disease. Nat Genet 2013;45:214-219. 
[30] Baruffini E, C Dallabona, F Invernizzi, JW Yarham, L Melchionda, EL Blakely, et 
al. MTO1 mutations are associated with hypertrophic cardiomyopathy and lactic acidosis and 
cause respiratory chain deficiency in humans and yeast. Hum Mutat 2013;34:1501-1509. 
[31] Danhauser K, A Iuso, TB Haack, P Freisinger, K Brockmann, JA Mayr, et al. Cellular 
rescue-assay aids verification of causative DNA-variants in mitochondrial complex I 
deficiency. Mol Genet Metab 2011;103:161-166. 
[32] Baker MJ, CS Palmer, D Stojanovski. Mitochondrial protein quality control in health 
and disease. Br J Pharmacol 2014;171:1870-1889. 
[33] Zara V, L Conte, BL Trumpower. Biogenesis of the yeast cytochrome bc1 complex. 
Biochim Biophys Acta 2009;1793:89-96. 
[34] Elstner M, C Andreoli, T Klopstock, T Meitinger, H Prokisch. The mitochondrial 
proteome database: MitoP2. Methods Enzymol 2009;457:3-20. 
[35] Sanchez E, T Lobo, JL Fox, M Zeviani, DR Winge, E Fernandez-Vizarra. 
LYRM7/MZM1L is a UQCRFS1 chaperone involved in the last steps of mitochondrial 
Complex III assembly in human cells. Biochim Biophys Acta 2013;1827:285-293. 
[36] Ghezzi D, E Baruffini, TB Haack, F Invernizzi, L Melchionda, C Dallabona, et al. 
Mutations of the Mitochondrial-tRNA Modifier MTO1 Cause Hypertrophic Cardiomyopathy 
and Lactic Acidosis. Am J Hum Genet 2012. 
[37] Umeda N, T Suzuki, M Yukawa, Y Ohya, H Shindo, K Watanabe, et al. 
Mitochondria-specific RNA-modifying enzymes responsible for the biosynthesis of the 
wobble base in mitochondrial tRNAs. Implications for the molecular pathogenesis of human 
mitochondrial diseases. J Biol Chem 2005;280:1613-1624. 
22 
 
[38] Li X, R Li, X Lin, MX Guan. Isolation and characterization of the putative nuclear 
modifier gene MTO1 involved in the pathogenesis of deafness-associated mitochondrial 12 S 
rRNA A1555G mutation. J Biol Chem 2002;277:27256-27264. 
[39] Bonnefont JP, NB Specola, A Vassault, A Lombes, H Ogier, JB de Klerk, et al. The 
fasting test in paediatrics: application to the diagnosis of pathological hypo- and hyperketotic 
states. Eur J Pediatr 1990;150:80-85. 
[40] Hinson JT, VR Fantin, J Schonberger, N Breivik, G Siem, B McDonough, et al. 
Missense mutations in the BCS1L gene as a cause of the Bjornstad syndrome. N Engl J Med 
2007;356:809-819. 
[41] Fernandez-Vizarra E, M Bugiani, P Goffrini, F Carrara, L Farina, E Procopio, et al. 
Impaired complex III assembly associated with BCS1L gene mutations in isolated 
mitochondrial encephalopathy. Hum Mol Genet 2007;16:1241-1252. 
[42] Wagener N, W Neupert. Bcs1, a AAA protein of the mitochondria with a role in the 
biogenesis of the respiratory chain. Journal of structural biology 2012;179:121-125. 
[43] Osawa T, K Ito, H Inanaga, O Nureki, K Tomita, T Numata. Conserved cysteine 
residues of GidA are essential for biogenesis of 5-carboxymethylaminomethyluridine at tRNA 
anticodon. Structure 2009;17:713-724. 
Author names in bold designate shared co-first authorship. 
  
23 
 
Table 1: OXPHOS activities in liver and fibroblasts 
Assay Patient’s 
liver 
Control livers 
[n=28] 
Patient’s 
fibroblasts [n=4] 
Control 
fibroblasts [n=70] 
CI 54 29±10 (19-44) NA NA 
CII 105 137±48 (77-198) 27±3 (24-30) 28±10 (15-40) 
CIII 0 63±21 (41-89) 14±11 (2-21) 54±21 (30-79) 
CIV  88 75±27 (47-117) 55±20 (37-77) 82±21 (57-106) 
II+III 16 59±22 (38-81)  25±3 (22-27) 30±8 (20-41) 
CS 93 68±29 (29-107) 68±8 (60-75) 78±25 (51-106) 
III/CS 
 
IV/CS 
 
III/II 
 
III/ IV 
0 
 
0.95 
 
0 
 
0 
1.13±0.81 
(0.45-2.10) 
1.26±0.55 
(0.58-1.17) 
0.52±0.32 
(0.22-0.91) 
0.93±0.53 
(0.48-1.60) 
0.20±0.15 
(0.03-0.29) 
0.76±0.24 
(0.62-0.99) 
0.51±0.37 
(0.09-0.74) 
0.20±0.17 
(0.06-0.37) 
0.78±0.33 
(0.32-1.42) 
1.11±0.29 
(0.81-1.47) 
2.06±0.97 
(0.85-3.98) 
0.72±0.30 
(0.40-1.09) 
Apart from the results in the Patient’s liver that were obtained only once, values are given as 
median ±standard deviation and as range between 10th and 90th centile between brackets; the 
number of different control values is given between square brackets in the column title; 
numbers in bold significantly differed from controls using mean comparison with Mann and 
Whitney test; CI=complex I or rotenone sensitive NADH ubiquinone oxidoreductase activity; 
CII= complex II or succinate ubiquinone oxidoreductase activity; CIII= complex III or 
antimycine sensitive ubiquinol cytochrome C oxidoreductase activity; CIV= complex IV or 
cytochrome C oxidase activity; II+III= combined II+III or succinate cytochrome C 
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oxidoreductase activity; CS= citrate synthase, a Krebs cycle enzyme used as an indicator of 
the mitochondrial content; apart from the ratios to citrate synthase, results are expressed as 
nanomoles per minute and milligram protein of either the liver post-nuclear supernatant or the 
whole fibroblast homogenate.  
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Table 2: Expected consequences of the LYRM7 and MTO1 genes mutations on the 
proteins  
LYRM7 (NM_181705.3) Nter domain  
“H sapiens”  1 MGRAVKVLQLFKTLHRTRQQVFKNDARALEAARIKINEEFKNNKSETSSK 
“Patient”  1 MGRAVKVLQLFKTLHRTDNKFLKMMPEH* 
“P troglodytes” 1 MGRAVKVLQLFKTLHRTRQQVFKNDARALEAARIKINEEFKNNKSETSSK 
“M musculus” 1 MGQPAKVLQLFKTLHRTRQQVFKNDKRALEAARVKINEEFKKHKNETSPE 
“B taurus”  1 MGQAAKVLQLFKTLHRTRQQVFKNDARALEAARKKINEEFKCNKTETSPK 
“C lupus”  1 MGQAAKVLQLFKTLHRTRQQVFKNDTRALEAARIKINEEFKSNKSETSPK 
“D melanogaster”  1 -----QVLSAFKKLHRTRQYVFQGDANALAAGRLKINESFLQNRNESS 
“C elegans”  1 MRRSRRVLQ--RVTNRLREKNFKTIQRARTMRKRAASAKARNEFSPPAYQSKNNSTE 
“S cerevisiae” 1 ------VASLF--LPYTPQFEADVTNSDTAKLVESSMIKVDCNNQELSNNKQERSS 
MTO1 (NM_012123.3) Cter domain 
“H sapiens”  VTPAAIINLLRFVKTTQRRQSAMNESSKTDQYLCDADRLQEREL 
“Patient”  VTPAAIINLLRFVKTTQ* 
“P troglodytes “ VLPSAIINEISF—TTKVPQKYENEN 
“M musculus” VTPAAIINLLRFVRSTRQSRQ 
“B taurus”  VTAAAIVNLLRFVKTTQQRQAAMN 
“C lupus”  VTPAAIINLLRFVKTTQQKQMAIN 
“D melanogaster” VSPEAIAEL-RPVIQKLSMTQRRQLEIKES 
“C elegans”  VVNAAIL-IVSFLSTTQRK 
“S cerevisiae” VTPV-IISLRRYIKTSTNVKLNKRLSTVVEKLNQNS 
Only the region affected by the mutation are shown (N`-terminus for LYRM7 and C`-
terminus for MTO1). LYRM7 frameshift mutation induces a change of 10 of the aminoacids 
from position 18 to 28 followed by a stop codon at amino acid position 29; it therefore 
drastically modifies the protein that normally comprises 104 aminoacids. MTO1 mutation 
changes Arg666 into a stop, it thus truncates the protein of its 27 last amino acids. Both 
LYRM7 and MTO1 proteins are, as a whole, very well conserved among mammals. The C`-
terminal domain of MTO1 does not appear conserved. The patient’s deletion however 
removes the last part of MTO1 GidA-associated domain, which has been proposed to bind 
tRNA [43] 
26 
 
Table 3: Genetic complex III defects sharing their clinical pattern 
Sign/symptom UQCRB[12] CYC1[13] UQCRC2[14] LYRM7£[18] 
Age at onset 8 5/28 NN/NN/NN 20/6 
Present age 18 3/21 5/4/1.5 2.3*/1.2* 
Metabolic crises 
Severe acidosis 
Hyperlactatemia 
Hypoglycemia 
Hyperammonemia 
Ketosis 
+£ 
+ 
+ 
+ 
± 
+ 
+/+£ 
+/+ 
+/+ 
±/+ 
+/+ 
+/+ 
+/+/+££ 
+/+/+ 
+/+/+ 
+/+/+ 
+/+/? 
+/+/? 
+/+ 
+/+ 
+/+ 
?/+ 
+/? 
?/? 
Liver failure ± 0/± 0/0/0 0/0 
Brain function N N N/N/N PR$/PR$$ 
Heart function N N N N 
Complex III  
Liver 
Skeletal Muscle 
Fibroblasts 
 
6% 
? 
12% 
 
4%/? 
24%/45% 
25%/24% 
 
? 
? 
50%/?/? 
 
?/0% 
22%/? 
?/26% 
0= absence of the sign; N=Normal function; Age at onset is expressed in months or as NN for 
neonatal period; present age is expressed in years, *=age at death; frequency of acute 
metabolic crises was reported as ~ four times a year from 0.5 to 4 years of age, progressively 
declining to less than one per year during adolescence (£) or as frequent and decreasing with 
age (££);severe acidosis=pH dropping to ~7.0 or below; ± liver failure= factor V<40% only 
observed during one acute metabolic crisis; PR=Psychomotor Regression, ($)=neurological 
development normal up to 20 months of age, severe psychomotor regression with loss of head 
control, spastic tetraparesis, marked demyelination and vacuolization of the white matter 
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appearing after an acute metabolic decompensation with pH 6.78; ($$)=neurological 
development normal up to 6 months of age, severe psychomotor regression with loss of 
contact, profound axial hypotonia and peripheral hypertonia following a 3 day-acute 
metabolic crisis with coma. £ During the preparation of this manuscript, 7 additional patients 
with LYRM7 mutations were identified based on the presence of a distinct multifocal 
leukoencephalopathy [19]. Metabolic crises were not reported in these patients who presented 
however with one or several episodes of subacute encephalopathy, during which metabolic 
parameters are not mentioned. 
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Figure legends 
Figure 1: Decreased amount of fully assembled respiratory complex III and altered ratio 
of complex III subunits in the patient’s fibroblasts 
C1,2,3= control fibroblasts, C’= fibroblasts from a patient with complex III defect associated 
with a MT-CYB variant, P=fibroblasts from the patient. 
(A) Blue native PAGE of crude mitochondrial pellets, CI = respiratory complex I, CII = 
complex II, CIII = complex III, CIV = complex IV, CV = complex V were revealed with 
antibodies against MT-ND1, SDHA, UQCRC2, MT-CO2 and ATPB respectively; the two 
bands of complex III correspond to monomers and dimers, both included in quantification; 
Quantification of Patient values (black bars), expressed as % of the mean value of controls of 
the same gel (white bars, error bars showing the maximum and minimum values). 
(B) SDS PAGE of whole cells homogenates, showing UQCRC2 and UQCRFS1, two complex 
III subunits respectively involved in early and late complex assembly; ACTB and SDHA are 
loading controls; quantification of the UQCRFS1/UQCRC2 ratio with white bars= controls 
and black bar=Patient.  
Figure 2: Both LYRM7 and MTO1 homozygous deleterious mutation segregated with the 
disease 
Electrophoregram of the gene sequence in the blood DNA of the different family members; 
MTO1 and LYRM7 mutations are homozygous in the patient, heterozygous in her two parents 
and one of her healthy sibling and absent in her second healthy sibling. 
Figure 3: Only LYRM7 expression restored complex III activity. 
Transduced lentivirus are indicated in the upper panel; A= Transcription assays by 
quantitative RT PCR, RNA data from two biological replicates were analyzed in triplicates, 
normalized to ACTB expression and expressed as fold of expression to non-transduced control 
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cells; B= Assays of mitochondrial activities, data from two biological replicates analyzed 
twice  
C= Control cells; P=Patient’s cells; non-transduced cells = white bars for the control, black 
bars for the patient; cells transduced with LYRM7-lentivirus = bars with horizontal lines, with 
MTO1-lentivirus = bars with vertical lines, with both LYRM7- and MTO1-lentiviruses = bars 
with diagonal lines *=p<0.05, **=p<0.01, ***=p<0.001 as compared to non-transduced 
control cells unless otherwise specified with brackets.  
Figure 4: LYRM7 expression restored UQCRFS1 expression  
A= Representative western blot analysis of purified mitochondria from control (C) and Patient 
(P) fibroblasts transduced with either LYRM7- or MTO1-lentivirus, alone or in association, as 
indicated below the western blot; specific bands are indicated with an arrow on the left side; 
B=quantification of the protein steady-state normalized to SDHA and to the non-transduced 
control mitochondria of the same gel; data from five independent experiments for LYRM7, 
MTO1, and UQCRFS1 and from two for UQCRC2; C= Control; P=Patient; mitochondria 
from non-transduced cells = white bars for control cells and black bars for patient’s cells; 
mitochondria from cells transduced with LYRM7-lentivirus = bars with horizontal lines, with 
MTO1-lentivirus = bars with vertical lines, with both LYRM7- and MTO1-lentiviruses = bars 
with diagonal lines; *=p<0.05, **=p<0.01, ***=p<0.001 as compared to non-transduced 
control cells. 
Figure 5: Intermediary metabolic pathways in prolonged fasting 
Main substrates of gluconeogenesis are show in bold, those involved in the malate-aspartate 
shuttle are underlined; Krebs intermediates are framed with a dotted line; PC= pyruvate 
carboxylase; ASAT= aspartate aminotransferase; CI= respiratory complex I, CII= complex II, 
CIII= complex III, CIV= complex IV; ETF ox and ETF red= electron transfer flavoprotein 
oxidized and reduced state. During prolonged fasting a defective complex III is bound to be 
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overloaded by the convergent increased electrons fluxes from activated gluconeogenesis and β 
oxidation. Redox potential increases, resulting in decreased flux in the Krebs cycle oxido-
reduction steps. Defect in gluconeogenic substrates induces hypoglycemia, defect in aspartate 
essential for argininosuccinate synthesis induces hyperammonemia and insufficient entry of 
acetylCoA into Krebs cycle induces ketosis. 
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Supplemental Figure 1: Mitochondrial activities of control cells are not 
significantly modified by empty lentiviruses and antibiotics
III=respiratory complex III activity; IV=respiratory complex IV activity; CS=citrate 
synthase activity; basal= no treatment and non-transduced cells, 
Upper panel shows activities after 48 hours treatment with 4 µg/mL blasticidin (blast) 
or 400 µg/mL neomycin (neo), or both.
Lower panel shows activities in cells transduced with empty lentiviruses coding only
for resistance to blasticidin (p.blast) or to neomycin (p.neo) or with both lentiviruses. 
Cells were selected during three weeks with the appropriate antibiotics. In each case 
data were obtained from two independent samples..
 
